当归饮子治疗慢性荨麻疹的Meta分析

Meta analysis on the treatment of chronic urticaria with Danggui Yinzi

目的系统评价当归饮子对比西药治疗慢性荨麻疹的疗效。方法计算机检索CNKI、维普、万方期刊全文数据库、EMbase数据库、PubMed、WebofScience引文数据库，收集当归饮子对比西药治疗慢性荨麻疹的临床随机对照试验中的相关数据，在严格质量评价的基础上，利用RevMan5．1软件进行Meta分析疗效及异质性检验；用倒漏斗图分析发表性偏倚，并进行敏感性分析。结果共13篇试验文献满足纳入标准，所有试验质量普遍不高，无双盲及分配隐藏。当归饮子对比西药有效率的效应值比值比OR=2．53，95％可信区间[1．92，3．34]；漏斗图提示存在发表性偏倚。结论当归饮子对比单纯西医常规治疗有一定疗效，但应进行严格的多中心随机双盲对照试验以提供更具说服力的证据。

Objective To assess the efficacy of Danggui Yinzi versus western medicine for treating chronic urticaria. Methods CNKI, VIP, Wanfang data, EMbase, the citation databases of PubMed, web of science updated to August 2012 were electronically searched. Randomized controlled trials （RCTs） and Clinical controlled trial （CCTs） on Danggui Yinzi and western medicine for chronic urticaria were identified. The quality of included RCTs and CCTs was assessed, and the meta-analysis was conducted with Revman5.1 software. Funnel-plot was used to identify the publication bias and performed sensitivity analyses. Results 13 trails involving 1042 patients were included. The qualities of all these trails were relatively low. There was no trail set double blinding and allocation concealment. Meta-analysis indicated that compared with western medicine, the effective rate ofDanggui Yinzi was superior to that of western medicine[OR=2.53, 95%CI（1.92, 3.34） ]. The funnel-plot demonstrated that there was publication bias. Conclusion The current evidence showed that Danggui Yinzi was superior to western medicine in efficacy, but we need more multicenter, randomized, double-blind trails to support it.